Poster Spotlight 8: Novel Insights into Breast Cancer
Session Details
Moderator
Popi Siziopikou, University of Arizona College of Medicine, Tucson, AZ
Moderator
Amrita Basu, University of California San Francisco, San Francisco, CA
Presentation numberPS8-1
Does pleomorphic ILC exist? Quantitative digital nuclear morphometry, molecular correlates, and clinical outcomes challenge a long-standing histologic paradigm
Lounes Djerroudi, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberPS8-2
Clinicopathologic Correlates of MammaPrint Risk Classification and Comparison with Oncotype DX in Invasive Lobular Carcinoma
Rachael Nakfoor, Cleveland Clinic, Cleveland, OH
Presentation numberPS8-3
Deep learning-based histomorphologic profiling reveals clinically relevant AI-defined breast cancer subgroups, including novel invasive lobular carcinoma phenotypes
Lounes Djerroudi, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberPS8-4
Histology-specific performance of genomic and digital pathology risk models in TAILORx
Ngoc-Kim Nguyen, University of Chicago, Chicago, IL
Presentation numberPS8-5
Single-cell subtyping of invasive lobular breast cancer by multicolor immunofluorescence – prognostic impact of proliferative heterogeneity in hormone receptor-negative tumor cells
Sofia Born, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany
Presentation numberPS8-6
ILC, a Unique Subtype
Hannah Wen, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberPS8-7
Hematoxylin-and-eosin-based AI risk stratification identifies patients with ER+/HER2- early-stage breast cancer who have a favorable treatment outcome on endocrine therapy alone, including those who meet NATALEE-like criteria: independent validation in ABCSG-8
Martin Filipits, Medical University of Vienna, Vienna, Austria
Presentation numberPS8-8
Multi-modal artificial intelligence (AI) predicts neoadjuvant response and long-term outcomes in HER2-positive early breast cancer (HER2+ EBC) treated with chemotherapy de-escalation strategies: analysis of the PHERGain trials.
Giulia Notini, IRCCS San Raffaele Hospital, Milan, Italy, Milano, Italy
Presentation numberPS8-9
Global Breast Cancer Screening Practices: Geographic Variation, Risk-Based Screening Implementation Gaps, and Clinician Perspectives on Artificial Intelligence
Berkay Demirors, University of Pittsburgh, Pittsburgh, PA
Presentation numberPS8-10
Artificial Intelligence (AI)-Based Identification of Invasive Lobular Carcinoma (ILC) Reveals Distinct Treatment and Recurrence Patterns in Two Randomized Breast Cancer Trials
Mishal Ali, University of Chicago, Chicago, IL
Presentation numberPS8-11
A Multimodal Clinical, Genomic, and Digital Pathology Model Improves Risk Stratification and Refines Chemotherapy Benefit Prediction in TAILORx
Ngoc Kim Nguyen, University of Chicago, Chicago, IL